Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1
Authors: Eric S. Daar, Ann A. Collier, Camlin Tierney
Journal: Annals of Internal Medicine (2011)

Letters20 September 2011Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1Eric S. Daar, MD, Ann A. Collier, MD, and Camlin Tierney, PhDEric S. Daar, MDFrom Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502; University of Washington Harborview Medical Center, Seattle, WA 98104, and Harvard School of Public Health, Boston, MA 02115-6017.Search for more papers by this author, Ann A. Collier, MDFrom Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502; University of Washington Harborview Medical Center, Seattle, WA 98104, and Harvard School of Public Health, Boston, MA 02115-6017.Search for more papers by this author, and Camlin Tierney, PhDFrom Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502; University of Washington Harborview Medical Center, Seattle, WA 98104, and Harvard School of Public Health, Boston, MA 02115-6017.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-155-6-201109200-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Flandre raises important points regarding the ACTG Study A5202 results; however, the abstract's conclusion does not stand alone. The Results section of the abstract and the Results and Discussion sections of the manuscript state that the equivalence boundary was not met. We do believe that the similarity in response rates is relevant to clinicians considering these treatment options. Differences in baseline HIV-1 RNA values have been addressed in a secondary analysis adjusting for this as continuous and categorical variables (<50 000 copies/mL, 50 000 to <100 000 copies/mL, 100 000 to <500 000 copies/mL, or ≥500 000 copies/mL), with the treatment effect estimate ...References1. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al; AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-106. [PMID: 18480202] CrossrefMedlineGoogle Scholar2. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services; 2011. Accessed at www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf on 18 May 2011. Google Scholar Author, Article, and Disclosure InformationAuthors: Eric S. Daar, MD; Ann A. Collier, MD; Camlin Tierney, PhDAffiliations: From Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502; University of Washington Harborview Medical Center, Seattle, WA 98104, and Harvard School of Public Health, Boston, MA 02115-6017.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-1780. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAtazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 Eric S. Daar , Camlin Tierney , Margaret A. Fischl , Paul E. Sax , Katie Mollan , Chakra Budhathoki , Catherine Godfrey , Nasreen C. Jahed , Laurie Myers , David Katzenstein , Awny Farajallah , James F. Rooney , Keith A. Pappa , William C. Woodward , Kristine Patterson , Hector Bolivar , Constance A. Benson , and Ann C. Collier , for the AIDS Clinical Trials Group Study A5202 Team* Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 Philippe Flandre Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 Ricardo S. Kuchenbecker , Marcelo Martins Reis , and Guilherme Barreiro Metrics 20 September 2011Volume 155, Issue 6Page: 403KeywordsConflicts of interestDisclosureDrugsHIVHIV-1Intent to treat analysisProteasesReverse transcriptase inhibitorsRNA ePublished: 20 September 2011 Issue Published: 20 September 2011 Copyright & PermissionsCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...